A drug that inhibits gastric acid secretion, containing a proton pump inhibitor.
Nolpaza inj., Producer: Krka
| form, dose, packaging | availability category | the active substance |
| powder for solution for intravenous injection; 40 mg; 1 vial | prescription drug | pantoprazole |
Indications
Reflux oesophagitis, gastric ulcer and / or duodenal ulcer, Zollinger-Ellison syndrome and other acid-related conditions.
Contraindications
Hypersensitivity to any of the ingredients of the preparation or to other drugs derived from benzimidazole.
Dosage
Intravenous administration is recommended only when pantoprazole cannot be taken orally. The available data are for intravenous use up to 7 days. The physician will replace the intravenous administration of the preparation with oral administration of pantoprazole tablets whenever possible.
Adults (intravenous administration over 2-15 minutes):
Gastric ulcer and / or duodenal ulcer and reflux oesophagitis: 40 mg intravenously daily.
Zollinger-Ellison syndrome and other conditions associated with excessive acid secretion: initially 80 mg intravenously daily, then the doctor will determine the dose individually based on the results of acid secretion tests in the stomach; If necessary, a short-term dose increase to more than 160 mg per day is possible. If doses are higher than 80 mg per day, they should be administered in 2 divided doses. Your doctor will determine the duration of treatment.
Due to the lack of sufficient clinical data, the preparation is not recommended for children and adolescents up to 18 years of age.
In people with severe hepatic insufficiency, the dose should not exceed 20 mg a day.
No dosage adjustment is necessary in the elderly or in those with renal impairment.